Payment overview · 2025
General Payments
$467.71
17 reported records · 9 companies
Healthcare provider profile · identity verified
Ragaa Iskarous, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DOWNEY, CA · NPI 1215035274
Verified facts
What the public records show
CMS Open Payments records show Ragaa Iskarous, M.D. received $467.71 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.59 | 30.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.05 | 15.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $55.10 | 11.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.12 | 11.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.76 | 7.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.79 | 7.4% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $28.96 | 6.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.38 | 5.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.96 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $467.71 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $116.75 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.12 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 513 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 74 |
| Celecoxib | Celecoxib | 214 | 68 |
| Metformin Hcl | Metformin Hcl | 199 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 58 |
| Gabapentin | Gabapentin | 185 | 57 |
| Lisinopril | Lisinopril | 166 | 48 |
| Ozempic | Semaglutide | 163 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 41 |
| Potassium Chloride | Potassium Chloride | 155 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 132 | 47 |
| Ketoconazole | Ketoconazole | 131 | 30 |
| Simvastatin | Simvastatin | 129 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 24 |
| Alendronate Sodium | Alendronate Sodium | 126 | 34 |
| Losartan Potassium | Losartan Potassium | 123 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 113 | 35 |
| Cyclosporine | Cyclosporine | 109 | 26 |
| Donepezil Hcl | Donepezil Hcl | 105 | 16 |
| Sertraline Hcl | Sertraline Hcl | 104 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 16 |
| Entresto | Sacubitril/Valsartan | 90 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 30 |
| Meclizine Hcl | Meclizine Hcl | 90 | 23 |
| Omeprazole | Omeprazole | 86 | 28 |
| Furosemide | Furosemide | 85 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 17 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 80 | suppressed |
| Baclofen | Baclofen | 77 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 14 |
| Glimepiride | Glimepiride | 75 | suppressed |
| Bumetanide | Bumetanide | 74 | 13 |
| Meloxicam | Meloxicam | 69 | 21 |
| Repaglinide | Repaglinide | 67 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Glipizide Er | Glipizide | 65 | 18 |
| Ibuprofen | Ibuprofen | 64 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Carvedilol | Carvedilol | 60 | 14 |
| Clonazepam | Clonazepam | 58 | 12 |
| Risedronate Sodium | Risedronate Sodium | 58 | 15 |
| Allopurinol | Allopurinol | 56 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 56 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Olanzapine | Olanzapine | 52 | suppressed |
| Jardiance | Empagliflozin | 51 | 16 |
| Ropinirole Er | Ropinirole Hcl | 51 | suppressed |
| Pregabalin | Pregabalin | 45 | 14 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | 11 |
| Finasteride | Finasteride | 40 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | suppressed |
| Prolia | Denosumab | 39 | 28 |
| Trazodone Hcl | Trazodone Hcl | 39 | 15 |
| Linzess | Linaclotide | 38 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | suppressed |
| Prednisone | Prednisone | 35 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Eliquis | Apixaban | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Famotidine | Famotidine | 29 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Cilostazol | Cilostazol | 28 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $467.71 · 17 records | Novo Nordisk Inc | EVENITY, GEMTESA, JARDIANCE, Kerendia, LifeVest, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, Wegovy, Xeomin, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error